Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q8ML
|
|||
| Drug Name |
ROR1 CAR-specific Autologous T-Lymphocytes
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 1 | [1] | |
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1 | [1] | ||
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1 | [1] | ||
| Company |
Fred Hutchinson Cancer Research Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neurotrophic tyrosine kinase ROR1 (ROR1) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Wnt signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.